Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

1
Crius Energy Trust Comments on Unusual Market Activity

2018-07-17 globenewswire
TORONTO, July 17, 2018 (GLOBE NEWSWIRE) -- Crius Energy Trust ("Crius Energy" or the "Trust") (TSX:KWH.UN) is issuing this news release in light of unusual trading activity related to the trust units of Crius Energy ("Units") on the Toronto Stock Exchange.
KWH.UN CRIUF

1
Crius Energy Trust Announces Voting Results of 2018 Annual and Special Meeting

2018-05-29 globenewswire
TORONTO, May 29, 2018 (GLOBE NEWSWIRE) -- Crius Energy Trust ("Crius" or the "Trust") (TSX:KWH.UN) is pleased to announce the results of voting at the annual and special meeting (the "Meeting") of unitholders of the Trust ("Unitholders") held on May 29, 2018. A total of 21,730,663 units of the Trust ("Units") were present in person or represented by proxy at the Meeting, representing approximately 38.
KWH.UN CRIUF

0
BRIEF-Crius Energy Will Seek Unitholder Approval Of Amendments Proposed By JCP Investment Management

2018-04-19 reuters
* CRIUS ENERGY TRUST - WILL SEEK UNITHOLDER APPROVAL OF CERTAIN GOVERNANCE AMENDMENTS PROPOSED BY JCP INVESTMENT MANAGEMENT Source text for Eikon: Further company coverage:
KWH.UN CRIUF

0
Crius to Put Forward Governance Amendments for Unitholder Approval at Annual General Meeting 

2018-04-19 globenewswire
TORONTO, April 19, 2018 (GLOBE NEWSWIRE) -- Crius Energy Trust (TSX:KWH.UN) (the "Trust", "Crius" or the "Company") today announced that it will seek unitholder approval of certain governance amendments proposed by dissident unitholder JCP Investment Management, LLC (“JCP”). Unitholders will have the opportunity to vote on the amendments at Crius’ Annual General Meeting (“AGM”) on May 29, 2018.
KWH.UN CRIUF

0
BRIEF-Crius Announces TSX Approval Of Normal Course Issuer Bid

2018-03-27 reuters
* CRIUS ENERGY TRUST - TORONTO STOCK EXCHANGE HAS APPROVED TRUST’S NOTICE OF INTENTION TO MAKE A NORMAL COURSE ISSUER BID
KWH.UN CRIUF

0
Controversial Monthly Payer Yields 11%, Big Q4 '17 Earnings, No K-1, Goes Ex This Week

2018-03-25 seekingalpha
These trust units have tanked in 2018 due to a short seller hit piece. But this has created a buying opportunity.
KWH.UN CRIUF

0
Crius Energy Trust 2017 Q4 - Results - Earnings Call Slides

2018-03-12 seekingalpha
The following slide deck was published by Crius Energy Trust in conjunction with their 2017 Q4 earnings call.
KWH.UN CRIUF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...